{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.1","upperLimit":"53.4","value":"28.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"description":"Duration of Response (calculated for responders only) is defined as the time from the initial documented response (partial response or better) to confirmed disease progression by the investigator based on IMWG criteria.","dispersionType":"95% Confidence Interval","groups":[{"description":"Oral pomalidomide 4 mg on Days 1-21 of 28-day cycle until progressive disease (PD) or unacceptable toxicity\n\npomalidomide: Oral pomalidomide 4 mg on Days 1-21 of 28-day cycle until progressive disease (PD) or unacceptable toxicity","id":"OG000","title":"Pomalidomide"}],"paramType":"MEDIAN","populationDescription":"Includes those who had a partial response or better.","reportingStatus":"POSTED","timeFrame":"From randomization through the study follow-up phase; up to the data cut-off of 31 July 2014; Maximum duration of response follow-up was 90.3 weeks.","title":"Kaplan-Meier Estimate Duration of Response Based on Investigator Assessment Using IMWG Criteria","type":"SECONDARY","unitOfMeasure":"weeks"}